289 related articles for article (PubMed ID: 12874969)
1. The habits of successful bioentrepreneurs.
Hodgson J; Ward M
Nat Biotechnol; 2003 Jul; 21 Suppl():BE3-5. PubMed ID: 12874969
[No Abstract] [Full Text] [Related]
2. The money men.
Alper J
Nat Biotechnol; 2003 Jul; 21 Suppl():BE7-12. PubMed ID: 12874970
[No Abstract] [Full Text] [Related]
3. Filters for preparing to meet a venture capitalist.
Christoffersen R
Nat Biotechnol; 2003 Jul; 21 Suppl():BE49-50. PubMed ID: 12874981
[No Abstract] [Full Text] [Related]
4. Convincing a venture capitalist to invest in your idea.
Dooley JF; Dooley JF
Nat Biotechnol; 2003 Jul; 21 Suppl():BE45-8. PubMed ID: 12874980
[No Abstract] [Full Text] [Related]
5. Biotechnology financing dilemmas and the role of special purpose entities.
Schiff L; Murray F
Nat Biotechnol; 2004 Mar; 22(3):271-7. PubMed ID: 14990945
[No Abstract] [Full Text] [Related]
6. Ancillary services: the prescription for a difficult business climate.
Krizner T
Med Econ; 2013 Aug; 90(15):58-60, 62. PubMed ID: 24730111
[No Abstract] [Full Text] [Related]
7. What every CFO should know about equipment financing.
Philbrick JA
Nat Biotechnol; 2004 Oct; 22(10):1325-6. PubMed ID: 15521097
[No Abstract] [Full Text] [Related]
8. Cash-strapped biotechs find financing alternative.
Mitchell P
Nat Biotechnol; 2004 Sep; 22(9):1057-8. PubMed ID: 15340452
[No Abstract] [Full Text] [Related]
9. The startup balancing act: hiring the right talent.
Moroney S
Nat Biotechnol; 1998 May; 16 Suppl():39-40. PubMed ID: 9591265
[No Abstract] [Full Text] [Related]
10. Boutiques reborn in 2003.
Surendran A
Nat Biotechnol; 2004 Mar; 22(3):353-4. PubMed ID: 15017987
[No Abstract] [Full Text] [Related]
11. The term sheet tango.
Willey T; Parsigian D
Nat Biotechnol; 2003 Jul; 21 Suppl():BE29-30. PubMed ID: 12874974
[No Abstract] [Full Text] [Related]
12. Is Elan a turnaround?
Jacobs T
Nat Biotechnol; 2003 Sep; 21(9):985. PubMed ID: 12949557
[No Abstract] [Full Text] [Related]
13. Navigating biotechnology's new fiscal opportunities.
Purcell DJ
Nat Biotechnol; 1998 May; 16 Suppl():51-3. PubMed ID: 9591271
[No Abstract] [Full Text] [Related]
14. Writing your business plan.
Cohen L
Nat Biotechnol; 2002 Jul; 20 Suppl():BE33-5. PubMed ID: 12089584
[No Abstract] [Full Text] [Related]
15. Can Europe accelerate out of trouble?
Nat Biotechnol; 2006 Sep; 24(9):1040. PubMed ID: 16964194
[No Abstract] [Full Text] [Related]
16. Intellectual property as a foundation for funding.
Meltzer SL; Marks MS; McCormick JT
Nat Biotechnol; 2002 Jul; 20 Suppl():BE47-50. PubMed ID: 12089588
[No Abstract] [Full Text] [Related]
17. The stampede to convertibles.
Jacobs T
Nat Biotechnol; 2003 Aug; 21(8):855. PubMed ID: 12894195
[No Abstract] [Full Text] [Related]
18. The capital campaign.
Thompson RL
J Natl Assoc Hosp Dev; 1984; ():66-8. PubMed ID: 10310420
[No Abstract] [Full Text] [Related]
19. Does biotech M&A benefit investors?
Jacobs T
Nat Biotechnol; 2004 Sep; 22(9):1085. PubMed ID: 15340472
[No Abstract] [Full Text] [Related]
20. The rise of European venture capital for biotechnology.
Howell M; Trull M; Dibner MD
Nat Biotechnol; 2003 Nov; 21(11):1287-91. PubMed ID: 14595356
[No Abstract] [Full Text] [Related]
[Next] [New Search]
